Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone
Table 4
Patients presenting with primary sarcoma of the bone without evident metastatic disease who subsequently developed indeterminant nodules on CT scan of the chest: comparison between the subgroup that developed metastatic disease vs. those that did not.
Patients who developed indeterminant nodules on follow-up CT scans of the chest who then developed metastatic disease
Patients who developed indeterminant nodules on follow-up CT scans of the chest but did not develop metastatic disease
value
N
32
26
Age (years)
48.3 (19–81)
51.1 (16–79)
0.622
Follow-up (months)
37.3 (2–107)
45.2 (2–192)
0.579
Gender
Male
19 (59.4%)
15 (57.7%)
0.897
Female
13 (40.6%)
11 (42.3%)
Smoking history
Never
21 (65.6%)
17 (65.4%)
0.967
+Smoking history
8 (25.0%)
7 (26.9%)
Unknown
3 (9.4%)
2 (7.7%)
Diagnosis
Osteosarcoma
8 (25.0%)
6 (23.1%)
0.761
Chondrosarcoma
11 (34.4%)
12 (46.2%)
Ewing sarcoma
4 (12.5%)
1 (3.8%)
Chordoma
2 (6.3%)
2 (7.7%)
Others
7 (21.9%)
5 (19.2%)
Grade
Low
1 (3.1%)
2 (7.7%)
0.435
High
31 (96.9%)
24 (92.3%)
Anatomic location
Upper extremity
3 (9.4%)
8 (30.8%)
0.219
Lower extremity
13 (40.6%)
9 (34.6%)
Spine/Chest wall
3 (9.4%)
2 (7.7%)
Pelvis
13 (40.6%)
7 (26.9%)
Presence of indeterminant nodules on preoperative CT chest
Yes
13 (40.6%)
12 (46.2%)
0.672
No
19 (59.4%)
14 (53.8%)
Size of largest nodule on preoperative CT chest
1–5 mm
12 (92.3%)
8 (66.7%)
0.212
6–9 mm
0 (0%)
2 (16.7%)
10+ mm
1 (7.7%)
2 (16.7%)
Time to development of indeterminant nodule from surgery (months)
15.5 (1–84)
14.3 (1–48)
0.650
Size of largest nodule each patient developed on surveillance CT chest
1–5 mm
11 (34.4%)
19 (73.1%)
0.014
6–9 mm
11 (34.4%)
5 (19.2%)
10+ mm
10 (31.3%)
2 (7.7%)a
Number of nodules each patient developed on surveillance CT chest
1
9 (28.1%)
17 (65.4%)
0.021
2
6 (18.8%)
4 (15.4%)
3
5 (15.6%)
4 (15.4%)
4
4 (12.5%)
1 (3.8%)
5+
8 (25.0%)
0 (0%)
value: comparison of patients presenting with indeterminant nodules who went on to develop metastatic disease vs. those who did not develop metastatic disease, performed with Chi-square and Mann–Whitney U tests.
